Immunotherapy, or the notion of "retraining" patients' immune systems, constitutes a major step forward in the fight against cancer. Although the results of CAR T cell therapy are very positive, its efficacy is still difficult to predict. Research by scientists at the Institut Pasteur has improved our understanding of how these cells function. 

L’immunothérapie, ou l’idée de « rééduquer » le système immunitaire d’un patient, est une avancée majeure dans la lutte contre le cancer. La thérapie par cellule CAR T montre de très bon résultat mais son efficacité reste difficile à prédire. Des travaux de chercheurs de l’Institut Pasteur ont permis de mieux appréhender le fonctionnement de ces cellules.

The human body is made up of tens of thousands of billions of cells, all originating from the division of one parent cell into two daughter cells. Scientists from the Institut Pasteur set out to investigate midbodies, which are key cell division structures, and they identified the role of BST2, a restriction factor involved in viral infections.

ERA4TB (the European Regimen Accelerator for Tuberculosis) is a 6-year public-private partnership with a total budget of over €200M that began in 2020 with the goal of accelerating the development of new treatment regimens for tuberculosis (TB). As part of the Innovative Medicines Initiative, ERA4TB brings together experts from academia and pharma, led by Stewart Cole (Institut Pasteur) and David Barros-Aguirre (GlaxoSmithKline).

L’organisme humain est constitué de dizaines de milliers de milliards de cellules, toutes issues de la division successive d’une cellule mère en deux cellules filles. Des chercheurs de l’Institut Pasteur ont étudié les midbodies, structures clés dans cette division cellulaire. Ils ont identifié le rôle de BST2, un facteur de restriction impliqué dans les infections virales.

Two projects have been accepted into the Institut Pasteur Innovation Accelerator, an initiative to improve the development potential of the Institut Pasteur's research: a highly automated technological system involving bioassays and a partnership based on a French startup studio.

Une activité technologique fortement automatisée autour des bioessais et un partenariat autour d’un startup studio français : voici les deux projets qui viennent renforcer l’Accélérateur d’innovation pasteurienne, un dispositif qui vise à améliorer le potentiel de développement des activités de recherche de l’Institut Pasteur.

The Institut Pasteur's Systems Biology Group is a partner in a new international project on applications of artificial intelligence (AI) for the diagnosis and treatment of ovarian cancer. The project, entitled DECIDER, has been granted five-year funding by the European Union.

Tuberculosis is one of the most deadly infectious diseases in the world, and it is the most deadly disease in Europe's history. It is generally caused by the Mycobacterium tuberculosis bacterium. Scientists have studied the impact of tuberculosis outbreaks on the human genome over the past 10,000 years.

The Institut Pasteur is a scientific partner of Argobio Studio, a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years. Argobio will incubate early-stage, highly innovative therapeutic projects up to company creation and Series A venture funding in selected therapeutic areas.